ReviewTherapeutic delivery2020
COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics.
Review in Therapeutic delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05739513 (A Specific miRNA Encoded by SARS-CoV-2 as a Diagnostic Tool to Predict Disease Severity in COVID-19 Patients), which is not on this map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Specific miRNA Encoded by SARS-CoV-2 as a Diagnostic Tool to Predict Disease Severity in COVID-19 Patients
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019.Medicine · 2020Pooled it
- Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.BMC infectious diseases · 2020Trial
- Review
- Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.Journal of pharmacological sciences · 2023Review
- A perspective on SARS-CoV-2 virus-like particles vaccines.International immunopharmacology · 2023Review
- Fear, Anxiety and Depression among Bosnia and Herzegovina Citizens during the Third Wave of COVID-19.Iranian journal of psychiatry · 2023Article
- COVID-19 knowledge, attitude, and preventive practices among government and private bank workers in Ethiopia.Frontiers in public health · 2023Article
- An update on SARS-CoV-2 immunization and future directions.Frontiers in pharmacology · 2023Review
- Article
- Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2.Bioprocess and biosystems engineering · 2022Review
- Article
- Article
- COVID-19: Perceived Infection Risk and Barriers to Uptake of Pfizer-BioNTech and Moderna Vaccines Among Community Healthcare Workers.Journal of racial and ethnic health disparities · 2022Article
- A cross-sectional investigation of the impact of COVID-19 on community pharmacy.Exploratory research in clinical and social pharmacy · 2022Article
- Article
- Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic.Osong public health and research perspectives · 2022Article
- Artesunate induces substantial topological alterations in the SARS-CoV-2 Nsp1 protein structure.Journal of King Saud University. Science · 2022Article
- Plant-Based Vaccines in Combat against Coronavirus Diseases.Vaccines · 2022Review
- Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis.Journal of biomolecular structure & dynamics · 2022Article
- Heterogeneity of the COVID-19 epidemic: what can we learn from it?American journal of translational research · 2022Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.